GSE115594 ML29755 RNA-seq data

Contributors : Frederike Bensch ; Elly L van der Veen ; Marjolijn N Lub-de Hooge ; Annelies Jorritsma-Smit ; Ronald Boellaard ; Iris C Kok ; Sjoukje F Oosting ; Carolina P Schr öder ; T N Hiltermann ; Anthonie J van der Wekken ; Harry M Groen ; Thomas C Kwee ; Sjoerd G Elias ; Jourik A Gietema ; Sandra Sanabria Bohorquez ; Alex de Crespigny ; Simon-Peter Williams ; Christoph Mancao ; Adrienne H Brouwers ; Bernard M Fine ; Elisabeth E de VriesSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensProgrammed death-ligand 1 (PD-L1) expression has been associated with response to PD-1/PD-L1 inhibition, but responses are also seen in patients with PD-L1 negative tumors when assessed immunohistochemically (IHC) with various antibodies. To help elucidate these findings, we performed a positron emission tomography (PET) imaging study in human with the anti-PD-L1 antibody atezolizumab labeled with Zirconium-89 (89Zr) prior to treatment with atezolizumab to assess normal tissue distribution and evaluate tumor tracer uptake. Additionally, to help explain why some patients respond to checkpoint inhibitors despite low or absent PD-L1 expression, we compared PD-L1 expression and immune phenotypes based on both CD8 IHC and RNA sequencing of post-tracer biopsies to tumor tracer uptake (SUVmax).

Source: GEO: Gene Expression Omnibus - June 12, 2018 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research